Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Contact: Study coordinator (Site Public Contact) · cancer@cchmc.org · 513-636-2799
Contact: Principal Investigator (John Perentesis, MD)
Laura Agresta, MD (Sub-investigator)

Study leads

John Perentesis, MD
Principal Investigator
Children's Hospital Medical Center, Cincinnati

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE1, PHASE2

Houston, United States

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Leukemia · Relapsed Leukemia · Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Boston, United States

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute · AML Stage, Adult

Abroad (travel likely)RecruitingPHASE2

Xiamen, China

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1

Nanchang, China · Nanchang, China